Table 4. Demographic data for the cohorts employed in this study and analysis plan.
| N | Age±SD | Age*(range) | Sex (Fe) | APOE4+ | Analysis | ||
|---|---|---|---|---|---|---|---|
|
Familial KANL & ADSP |
1582 | ||||||
| Cases | 1090 | 72.30±9.20 | 36–99 | 63% | 72% | Discovery | |
| Controls | 441 | 83.95±8.95 | 39–104 | 58% | 52% | ||
| Other | 51 | 88.18±8.70 | 66–108 | 61% | 50% | ||
|
Sporadic KANL |
801 | ||||||
| Cases | 424 | 66.13±9.77 | 43–89 | 49% | 60% | Discovery | |
| Controls | 377 | 71.93±10.11 | 41–106 | 57% | 37% | ||
|
Unrelated KANL |
1235 | ||||||
| Cases | 672 | 65.59±9.29 | 36–98 | 52% | 70% | GENE-based | |
| Controls | 563 | 77.46±8.63 | 41–106 | 55% | 40% | ||
|
Sporadic ADSP |
10909 | Discovery | |||||
| Cases | 5844 | 75.50±9.33 | 40–107 | 58% | 42% | ||
| Controls | 4767 | 86.78±5.47 | 42–107 | 59% | 15% | ||
| Other | 298 | 86.19±6.73 | 64–104 | 57% | 25% | ||
|
Sporadic ADSP (EU only) |
10280 | GENE-based | |||||
| Cases | 5679 | 75.51 ± 8.83 | 40–107 | 58% | 42% | ||
| Controls | 4601 | 84.72 ± 4.72 | 49–107 | 52% | 15% |
* Age At Onset (AAO) for cases and Age at Last Assessment (ALA) for controls.